A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
Clinical trial NCT02358096 · COMPLETED
Trial details
- NCT number
- NCT02358096
- Sponsor
- Astellas Pharma Europe B.V.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-17
- Primary completion
- 2016-10-26
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.